These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 20691481)

  • 41. Analysis of potentially predictive factors of efficacy of adjunct extended-release quetiapine fumarate in patients with major depressive disorder.
    Bauer M; Thase ME; Liu S; Earley W; Eriksson H
    J Psychopharmacol; 2015 May; 29(5):565-74. PubMed ID: 25257148
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tolerability of extended-release quetiapine fumarate compared with immediate-release quetiapine fumarate in older patients with Alzheimer's disease with symptoms of psychosis and/or agitation: a randomised, double-blind, parallel-group study.
    De Deyn PP; Eriksson H; Svensson H;
    Int J Geriatr Psychiatry; 2012 Mar; 27(3):296-304. PubMed ID: 21538537
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies.
    Vieta E; Mullen J; Brecher M; Paulsson B; Jones M
    Curr Med Res Opin; 2005 Jun; 21(6):923-34. PubMed ID: 15969892
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety of quetiapine fumarate extended release in the treatment of Korean patients with acute schizophrenia.
    Lee JG; Lee JI; Kim YT; Kim CE; Kim CY; Yoon JS; Yoo SY; Kim YH
    Hum Psychopharmacol; 2012 Jul; 27(4):403-10. PubMed ID: 22753400
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term symptomatic remission of schizophrenia with once-daily extended release quetiapine fumarate: post-hoc analysis of data from a randomized withdrawal, placebo-controlled study.
    Peuskens J; Trivedi JK; Brecher M; Miller F;
    Int Clin Psychopharmacol; 2010 May; 25(3):183-7. PubMed ID: 20216222
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study.
    Vieta E; Calabrese JR; Goikolea JM; Raines S; Macfadden W;
    Bipolar Disord; 2007 Jun; 9(4):413-25. PubMed ID: 17547587
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Extended-release quetiapine fumarate in the treatment of patients with major depressive disorder: adjunct therapy.
    Weisler R; McIntyre RS; Bauer M
    Expert Rev Neurother; 2013 Nov; 13(11):1183-200. PubMed ID: 24175721
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Extended release quetiapine fumarate as adjunct to antidepressant therapy in patients with major depressive disorder: pooled analyses of data in patients with anxious depression versus low levels of anxiety at baseline.
    Bandelow B; Bauer M; Vieta E; El-Khalili N; Gustafsson U; Earley WR; Eriksson H
    World J Biol Psychiatry; 2014 Feb; 15(2):155-66. PubMed ID: 24506289
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Number needed to treat and time to response/remission for quetiapine monotherapy efficacy in acute bipolar depression: evidence from a large, randomized, placebo-controlled study.
    Cookson J; Keck PE; Ketter TA; Macfadden W
    Int Clin Psychopharmacol; 2007 Mar; 22(2):93-100. PubMed ID: 17293709
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder: an analysis of pooled data from three 8-week placebo-controlled studies.
    Stein DJ; Bandelow B; Merideth C; Olausson B; Szamosi J; Eriksson H
    Hum Psychopharmacol; 2011 Dec; 26(8):614-28. PubMed ID: 22143997
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The role of quetiapine extended release in the treatment of bipolar depression.
    Cristancho MA; Thase ME
    Adv Ther; 2010 Nov; 27(11):774-84. PubMed ID: 20835785
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Quetiapine in the treatment of acute mania: target dose for efficacious treatment.
    Vieta E; Goldberg JF; Mullen J; Vågerö M; Paulsson B
    J Affect Disord; 2007; 100 Suppl 1():S23-31. PubMed ID: 17382403
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of once-daily extended release quetiapine fumarate (quetiapine XR) on quality of life and sleep in elderly patients with major depressive disorder.
    Locklear JC; Svedsäter H; Datto C; Endicott J
    J Affect Disord; 2013 Jul; 149(1-3):189-95. PubMed ID: 23639212
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Quetiapine monotherapy in the treatment of depressive episodes of bipolar I and II disorder: Improvements in quality of life and quality of sleep.
    Endicott J; Paulsson B; Gustafsson U; Schiöler H; Hassan M
    J Affect Disord; 2008 Dec; 111(2-3):306-19. PubMed ID: 18774180
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of quetiapine extended release on sleep and quality of life in midlife women with major depressive disorder.
    Frey BN; Haber E; Mendes GC; Steiner M; Soares CN
    Arch Womens Ment Health; 2013 Feb; 16(1):83-5. PubMed ID: 23143411
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparisons of the tolerability and sensitivity of quetiapine-XR in the acute treatment of schizophrenia, bipolar mania, bipolar depression, major depressive disorder, and generalized anxiety disorder.
    Wang Z; Kemp DE; Chan PK; Fang Y; Ganocy SJ; Calabrese JR; Gao K
    Int J Neuropsychopharmacol; 2011 Feb; 14(1):131-42. PubMed ID: 20875219
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pooled analysis of sustained response rates for extended release quetiapine fumarate as monotherapy or adjunct to antidepressant therapy in patients with major depressive disorder.
    Vieta E; Bauer M; Montgomery S; McIntyre RS; Szamosi J; Earley WR; Eriksson H
    J Affect Disord; 2013 Sep; 150(2):639-43. PubMed ID: 23497790
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and safety of extended-release quetiapine fumarate in youth with bipolar depression: an 8 week, double-blind, placebo-controlled trial.
    Findling RL; Pathak S; Earley WR; Liu S; DelBello MP
    J Child Adolesc Psychopharmacol; 2014 Aug; 24(6):325-35. PubMed ID: 24956042
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer's disease patients: a 6-week, double-blind, placebo-controlled study.
    Paleacu D; Barak Y; Mirecky I; Mazeh D
    Int J Geriatr Psychiatry; 2008 Apr; 23(4):393-400. PubMed ID: 17879256
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of low and moderate dosages of extended-release quetiapine in borderline personality disorder: a randomized, double-blind, placebo-controlled trial.
    Black DW; Zanarini MC; Romine A; Shaw M; Allen J; Schulz SC
    Am J Psychiatry; 2014 Nov; 171(11):1174-82. PubMed ID: 24968985
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.